T2	total-participants 499 502	235
T3	eligibility 503 538	women with metastatic breast cancer
T4	intervention 557 643	high-dose epirubicin 150 mg/m2 and cyclophosphamide 1500 mg/m2 with filgrastim support
T6	intervention-participants 865 868	118
T7	control-participants 955 958	117
T8	outcome 1033 1060	time to disease progression
T9	iv-cont-median 1062 1065	5.7
T10	cv-cont-median 1070 1080	5.8 months
T11	outcome 1095 1111	overall survival
T12	iv-cont-median 1113 1117	14.5
T13	cv-cont-median 1122 1133	16.5 months
T14	outcome 1214 1229	quality of life
T15	outcome 1341 1366	Objective tumour response
T16	iv-bin-abs 1383 1385	33
T17	iv-bin-percent 1387 1390	28%
T18	cv-bin-abs 1404 1406	42
T19	cv-bin-percent 1417 1420	36%
T20	outcome 1450 1471	haematologic toxicity
T1	outcome-Measure 803 822	time to progression
T21	outcome-Measure 824 840	overall survival
T22	outcome-Measure 845 860	quality of life
T5	control 774 778	SDEC
T23	location 1646 1656	Australian
T24	outcome 1514 1533	disease progression
T25	outcome 1535 1543	survival
T26	outcome 1547 1562	quality of life
